85656-64-0 Usage
General Description
8-Quinolinamine, 5-methyl-(9CI) is a chemical compound with the molecular formula C10H10N2. It belongs to the quinoline family of compounds and is also known by the name 5-methylquinolinamine. 8-Quinolinamine,5-methyl-(9CI) is a yellow powder that is sparingly soluble in water and soluble in organic solvents. It is commonly used in the pharmaceutical industry as an intermediate for the synthesis of various drugs. It also has potential applications in the field of material science and organic synthesis. However, due to its toxicity and potential health hazards, proper safety precautions should be taken when handling and using this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 85656-64-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,6,5 and 6 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 85656-64:
(7*8)+(6*5)+(5*6)+(4*5)+(3*6)+(2*6)+(1*4)=170
170 % 10 = 0
So 85656-64-0 is a valid CAS Registry Number.
85656-64-0Relevant articles and documents
Auxiliary-Directed C(sp3)?H Arylation by Synergistic Photoredox and Palladium Catalysis
Czyz, Milena L.,Lupton, David W.,Polyzos, Anastasios
, p. 14450 - 14453 (2017/10/07)
Herein we describe the auxiliary-directed arylation of unactivated C(sp3)?H bonds with aryldiazonium salts, which proceeds under synergistic photoredox and palladium catalysis. The site-selective arylation of aliphatic amides with α-quaternary centres is achieved with high selectivity for β-methyl C(sp3)?H bonds. This operationally simple method is compatible with carbocyclic amides, a range of aryldiazonium salts and proceeds at ambient conditions.
Novel Sulfonaminoquinoline Hepcidin Antagonists
-
Page/Page column 128, (2012/09/05)
The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.